Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Sham Injection
DRUG: Recombinant human hyaluronidase PH20
DRUG: Insulin aspart
DRUG: Insulin lispro

Sponsor

Halozyme Therapeutics